AU3519400A - Treatment of alpha-galactosidase a deficiency - Google Patents

Treatment of alpha-galactosidase a deficiency Download PDF

Info

Publication number
AU3519400A
AU3519400A AU35194/00A AU3519400A AU3519400A AU 3519400 A AU3519400 A AU 3519400A AU 35194/00 A AU35194/00 A AU 35194/00A AU 3519400 A AU3519400 A AU 3519400A AU 3519400 A AU3519400 A AU 3519400A
Authority
AU
Australia
Prior art keywords
gal
preparation
cells
glycoforms
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35194/00A
Other languages
English (en)
Inventor
Marianne Borowski
Peter F. Daniel
Carol M. Kinoshita
Thomas J. Schuetz
Richard F. Selden
Douglas A. Treco
Melanie D. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU3519400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of AU3519400A publication Critical patent/AU3519400A/en
Priority to AU2004242550A priority Critical patent/AU2004242550B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
AU35194/00A 1999-03-11 2000-03-09 Treatment of alpha-galactosidase a deficiency Abandoned AU3519400A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004242550A AU2004242550B2 (en) 1999-03-11 2004-12-31 Treatment of alpha-Galactosidase A deficiency

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/266,014 US6458574B1 (en) 1996-09-12 1999-03-11 Treatment of a α-galactosidase a deficiency
US09266014 1999-03-11
PCT/US2000/006118 WO2000053730A2 (en) 1999-03-11 2000-03-09 Medical preparations for the treatment of alpha-galactosidase a deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004242550A Division AU2004242550B2 (en) 1999-03-11 2004-12-31 Treatment of alpha-Galactosidase A deficiency

Publications (1)

Publication Number Publication Date
AU3519400A true AU3519400A (en) 2000-09-28

Family

ID=23012821

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35194/00A Abandoned AU3519400A (en) 1999-03-11 2000-03-09 Treatment of alpha-galactosidase a deficiency

Country Status (22)

Country Link
US (4) US6458574B1 (enExample)
EP (6) EP2186902B1 (enExample)
JP (6) JP2002538183A (enExample)
KR (2) KR100892334B1 (enExample)
CN (4) CN100417727C (enExample)
AT (1) ATE386808T1 (enExample)
AU (1) AU3519400A (enExample)
CA (3) CA2365923A1 (enExample)
CY (3) CY1107951T1 (enExample)
DE (1) DE60038104T2 (enExample)
DK (3) DK2186902T3 (enExample)
ES (3) ES2300256T3 (enExample)
HK (2) HK1043386B (enExample)
HU (1) HU228743B1 (enExample)
IL (2) IL145381A0 (enExample)
MX (1) MXPA01009222A (enExample)
NO (2) NO329689B1 (enExample)
NZ (1) NZ514077A (enExample)
PL (1) PL210833B1 (enExample)
PT (3) PT2314699T (enExample)
RU (1) RU2248213C2 (enExample)
WO (1) WO2000053730A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4641705B2 (ja) * 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ES2367257T3 (es) 2002-04-25 2011-10-31 Shire Human Genetic Therapies, Inc. Tratamiento de deficit de alfa-galactosidasa a.
US20060018882A1 (en) * 2004-06-21 2006-01-26 Kaemmerer William F Medical devices and methods for delivering compositions to cells
SI1589993T1 (sl) 2003-01-31 2015-05-29 Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
US7422310B2 (en) * 2003-04-25 2008-09-09 Hewlett-Packard Development Company, L.P. Methods and apparatus for selecting image enhancement techniques
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US20100196345A1 (en) * 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ES2344302T3 (es) 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CN1308444C (zh) * 2005-04-15 2007-04-04 中国人民解放军军事医学科学院野战输血研究所 基因重组α－半乳糖苷酶大批量发酵液的纯化方法
KR20080025373A (ko) 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법
US7935336B2 (en) 2005-11-18 2011-05-03 Tokyo Metropolitan Organization For Medical Research Highly functional enzyme having α-galactosidase activity
WO2007086067A1 (en) * 2006-01-30 2007-08-02 Diagnostic Technologies Ltd. Method for monitoring tocolytic treatment
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
BRPI0810343B1 (pt) * 2007-05-07 2021-03-30 Protalix Ltd Dispositivo descartável para o cultivo e colheita de tecidos vegetais e/ou células, método de cultivo e colheita de um tecido vegetal e/ou células vegetais em um volume maior do que 400 litros e sistema de cultivo da célula vegetal
EP2185187A1 (en) * 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
CN102066422B (zh) 2008-05-07 2015-07-22 宝玛瑞制药公司 溶酶体靶向肽及其应用
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2010148253A2 (en) 2009-06-17 2010-12-23 Zystor Therapeutics, Inc. Formulations for lysosomal enzymes
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP2542675B1 (en) * 2010-03-02 2014-12-17 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US20110293585A1 (en) * 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
KR101924120B1 (ko) 2010-07-08 2018-11-30 박스알타 인코퍼레이티드 세포 배양에서 재조합 ａｄａｍｔｓ13을 생산하는 방법
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
KR101913293B1 (ko) 2010-11-02 2018-10-30 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
US9376506B2 (en) 2011-03-04 2016-06-28 Glytech, Inc. Method for producing sialic-acid-containing sugar chain
LT2717893T (lt) 2011-06-08 2019-08-12 Translate Bio, Inc. Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
MX349992B (es) 2012-03-07 2017-08-22 Amicus Therapeutics Inc Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
ES2694681T3 (es) 2012-03-29 2018-12-26 The Trustees Of Columbia University In The City Of New York Métodos para tratar trastornos de pérdida capilar
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
CA2917995C (en) 2012-07-17 2021-01-26 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
WO2014152659A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
DK2971098T3 (en) 2013-03-14 2019-02-18 Translate Bio Inc QUANTITATIVE ASSESSMENT FOR CAPE EFFECTIVENESS OF MESSENGER RNA
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
KR102150481B1 (ko) * 2014-03-05 2020-09-02 울트라제닉스 파마수티컬 인코포레이티드 시알화 당단백질 조성물 및 이의 용도
HRP20250058T1 (hr) 2014-09-30 2025-03-28 Amicus Therapeutics, Inc. Vrlo snažna kisela alfa-glukozidaza s pojačanim ugljikohidratima
CA2971861C (en) * 2014-12-22 2024-02-13 Genzyme Corporation Methods of culturing a mammalian cell
ES2944889T3 (es) 2014-12-22 2023-06-26 Codexis Inc Variantes de alfa-galactosidasa humana
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
AU2017221405A1 (en) 2016-02-16 2018-09-20 Carnegie Mellon University Compositions for enhancing targeted gene editing and methods of use thereof
PE20190127A1 (es) 2016-03-30 2019-01-17 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p
JP7510743B2 (ja) 2016-03-30 2024-07-04 アミカス セラピューティックス インコーポレイテッド 組換え酸性α－グルコシダーゼを含む製剤
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
CA3039673A1 (en) * 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
HRP20230576T1 (hr) 2017-05-15 2023-09-01 Amicus Therapeutics, Inc. Rekombinantna ljudska kisela alfa-glukozidaza
WO2020047282A1 (en) * 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
WO2020132252A2 (en) * 2018-12-20 2020-06-25 Codexis, Inc. Human alpha-galactosidase variants
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)
TW202128264A (zh) * 2019-09-25 2021-08-01 瑞士商赫孚孟拉羅股份公司 使用經預測之溶離緩衝鹽濃度的陽離子層析法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322158B2 (enExample) * 1974-05-02 1978-07-06
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4740365A (en) 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en) 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
KR0159107B1 (ko) * 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
EP0446315B1 (en) * 1989-09-05 1997-06-11 Biotechnology Australia Pty. Ltd. Process for the preparation of pai-2
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
ES2107537T3 (es) 1991-04-25 1997-12-01 Univ Brown Res Found Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5858751A (en) 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
DK0641192T3 (da) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Anordning til transmucosal lægemiddelafgivelse
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
PT679088E (pt) 1992-09-29 2002-12-31 Inhale Therapeutic Syst Administracao pulmonar de fragmentos activos de hormona paratiroide
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) * 1993-09-23 1999-01-13 New England Biolabs Inc INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
EP0807165A4 (en) * 1995-01-30 1998-07-15 New York Blood Center Inc ENZYME -g (a) -GALACTOSIDASE RECOMBINANT
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
DE69732129T2 (de) 1996-09-13 2005-12-08 Transkaryotic Therapies, Inc., Cambridge THERAPIE FÜR alpha GALACTOSIDASE A INSUFFIZIENZ
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes

Also Published As

Publication number Publication date
PT2186902E (pt) 2012-08-28
WO2000053730A3 (en) 2001-03-15
KR100892334B1 (ko) 2009-04-08
NZ514077A (en) 2004-02-27
PL210833B1 (pl) 2012-03-30
KR20070090277A (ko) 2007-09-05
EP2186902A2 (en) 2010-05-19
EP1820862A2 (en) 2007-08-22
CY1113051T1 (el) 2016-04-13
HUP0200467A2 (en) 2002-06-29
CN101219213A (zh) 2008-07-16
EP2186902A3 (en) 2010-09-01
JP6626071B2 (ja) 2019-12-25
IL145381A (en) 2009-12-24
CA3012663A1 (en) 2000-09-14
PL350658A1 (en) 2003-01-27
NO20101493L (no) 2001-11-12
CN100417727C (zh) 2008-09-10
CY1107951T1 (el) 2013-09-04
NO20014415L (no) 2001-11-12
RU2248213C2 (ru) 2005-03-20
KR100961740B1 (ko) 2010-06-07
JP5899169B2 (ja) 2016-04-06
US20030113894A1 (en) 2003-06-19
EP3231871A1 (en) 2017-10-18
EP2186902B1 (en) 2012-05-23
NO329689B1 (no) 2010-11-29
PT1163349E (pt) 2008-05-19
JP5615648B2 (ja) 2014-10-29
CN1354796A (zh) 2002-06-19
EP2314699A1 (en) 2011-04-27
ATE386808T1 (de) 2008-03-15
DK2314699T3 (en) 2017-08-07
US20030077806A1 (en) 2003-04-24
ES2391221T3 (es) 2012-11-22
CA2833396C (en) 2018-08-28
JP2018038423A (ja) 2018-03-15
JP2011037867A (ja) 2011-02-24
EP1820862A3 (en) 2007-10-31
JP2013241466A (ja) 2013-12-05
US6458574B1 (en) 2002-10-01
EP2287319A1 (en) 2011-02-23
NO20014415D0 (no) 2001-09-11
JP6346236B2 (ja) 2018-06-20
CN103585621B (zh) 2016-08-10
EP2314699B1 (en) 2017-05-31
DK1163349T3 (da) 2008-06-23
CA2833396A1 (en) 2000-09-14
EP1163349A2 (en) 2001-12-19
IL145381A0 (en) 2002-06-30
JP2015091834A (ja) 2015-05-14
JP2002538183A (ja) 2002-11-12
US20110280856A1 (en) 2011-11-17
CA2365923A1 (en) 2000-09-14
DK2186902T3 (da) 2012-09-03
HUP0200467A3 (en) 2006-06-28
HK1245320A1 (en) 2018-08-24
CY1119369T1 (el) 2018-02-14
PT2314699T (pt) 2017-08-01
HU228743B1 (en) 2013-05-28
HK1043386B (en) 2008-06-13
HK1143833A1 (en) 2011-01-14
CN106110309A (zh) 2016-11-16
ES2300256T3 (es) 2008-06-16
KR20020021371A (ko) 2002-03-20
WO2000053730A2 (en) 2000-09-14
HK1043386A1 (en) 2002-09-13
JP2017014279A (ja) 2017-01-19
DE60038104T2 (de) 2009-02-12
ES2634317T3 (es) 2017-09-27
EP1163349B1 (en) 2008-02-20
CN103585621A (zh) 2014-02-19
MXPA01009222A (es) 2002-06-04
JP6081980B2 (ja) 2017-02-15
WO2000053730A9 (en) 2001-10-11
DE60038104D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
EP2186902B1 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
JP2015091834A5 (enExample)
AU2004242550B2 (en) Treatment of alpha-Galactosidase A deficiency
AU2016250357B2 (en) Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) Treatment of alpha-Galactosidase A deficiency
HK1154899A (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
HK1143833B (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
HK1154265A (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
AU2008202567A1 (en) Treatment of alpha-Galactosidase A deficiency